AEF-0217
- Generic Name
- AEF-0217
Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 40
- Registration Number
- NCT05748405
- Locations
- 🇪🇸
Unidad de Adultos con SÃndrome de Down, Hospital de La Princesa, Madrid, Spain
🇪🇸Hospital del Mar Medical Research Institute (IMIM),, Barcelona, Catalonia, Spain
🇪🇸Sant Pau Memory Clinic, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.
Phase 1
Completed
- Conditions
- Safety, Tolerability, Pharmacokinetics of AEF0217
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Aelis Farma
- Target Recruit Count
- 68
- Registration Number
- NCT05170737
- Locations
- 🇪🇸
Hospital del Mar Medical Research Institute (IMIM) Neurosciences Research Program, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath